fluorouracil + methotrexate + thiotepa

A combination chemotherapy regimen consisting of three anticancer drugs: 1. **5-Fluorouracil (5-FU)**: A pyrimidine analog that works as an antimetabolite, interfering with DNA synthesis and repair, causing cancer cells to die when they try to divide. 2. **Methotrexate (MTX)**: An antimetabolite chemotherapy drug that stops cells from making and repairing DNA, leading to cell death during division. 3. **Thiotepa**: An alkylating agent that works by destroying quickly dividing cells, such as cancer cells. This combination has been used primarily as a maintenance regimen in the treatment of metastatic breast cancer following induction therapy with other chemotherapy combinations. It has also been used in various cancer treatment protocols, including central nervous system lymphomas. The TMF regimen is typically administered intravenously, though specific administration schedules may vary depending on the treatment protocol and patient factors. While used in clinical practice, more recent treatment approaches may have superseded this specific combination in many clinical settings.

Brand names

TMF